Management and Outcomes of Society for Cardiovascular Angiography and Interventions Stage B Cardiogenic Shock

Chirag Mehta1, Phinnara Has2, Aryan Mehta3,4

  • 1Department of Medicine (C.M., I.V., B.O., A. Shin, V.C., S.C., D.D.P., A. Sweeting, R.T.), Warren Alpert Medical School of Brown University, Providence, RI.

Circulation. Heart Failure
|February 19, 2026
PubMed

Insights

A quarter of patients with Society for Cardiovascular Angiography and Interventions (SCAI) B cardiogenic shock deteriorated. Acute kidney injury and diuretic resistance predict worse outcomes in these patients.

Area of Science:

  • Cardiology
  • Critical Care Medicine
  • Clinical Research

Background:

  • Limited data exist on the etiology, management, and outcomes of Society for Cardiovascular Angiography and Interventions (SCAI) B cardiogenic shock.
  • SCAI B cardiogenic shock is characterized by hypotension or hypoperfusion in adult patients.

Purpose of the Study:

  • To evaluate the etiology, management, and outcomes of SCAI B cardiogenic shock.
  • To identify predictors of clinical deterioration in patients with SCAI B cardiogenic shock.

Main Methods:

  • A retrospective study of 500 adult patients with SCAI B cardiogenic shock from 2017-2022.
  • Defined SCAI B cardiogenic shock as hypotension (systolic ≤90/mean ≤65 mm Hg) or hypoperfusion (lactate 2-5 mEq/L), excluding cardiac arrest and circulatory support.
  • Used multivariable analysis and mixed-effects regression to identify predictors of a composite endpoint including transfer to higher care, SCAI stage escalation, or in-hospital mortality.

Main Results:

  • The most common etiologies were heart failure (37%), arrhythmia (23%), and acute myocardial infarction (13%).
  • A quarter of patients (135/500) experienced clinical deterioration.
  • Independent predictors of deterioration included acute kidney injury (aOR 2.17) and diuretic resistance (aOR 9.55). Patients with isolated hypotension had worse outcomes than those with isolated hypoperfusion.

Conclusions:

  • A quarter of patients with SCAI B cardiogenic shock experienced clinical deterioration.
  • Acute kidney injury and diuretic resistance within 24 hours were independently predictive of clinical deterioration.
  • These findings highlight key factors for monitoring and managing patients with SCAI B cardiogenic shock.
Abstract

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...